Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Andrew L, Pecora"'
Autor:
Michael B. Atkins, Sandra J. Lee, Bartosz Chmielowski, Ahmad A. Tarhini, Gary I. Cohen, Thach-Giao Truong, Helen H. Moon, Diwakar Davar, Mark O'Rourke, Joseph J. Stephenson, Brendan D. Curti, Walter J. Urba, Joanna M. Brell, Pauline Funchain, Kari L. Kendra, Alexandra P. Ikeguchi, Anthony Jaslowski, Charles L. Bane, Mark A. Taylor, Madhuri Bajaj, Robert M. Conry, Robert J. Ellis, Theodore F. Logan, Noel Laudi, Jeffrey A. Sosman, David G. Crockett, Andrew L. Pecora, Ian J. Okazaki, Sowjanya Reganti, Sunandana Chandra, Samantha Guild, Helen X. Chen, Howard Z. Streicher, Jedd D. Wolchok, Antoni Ribas, John M. Kirkwood
Publikováno v:
Journal of Clinical Oncology. 41:186-197
PURPOSE Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4–blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with BRAFV600-mutant metastatic melanoma, leading to broad regulatory a
Autor:
Andrew Ip, Alexandra Della Pia, Gee Youn (Geeny) Kim, Jason Lofters, James Behrmann, Dylon Patel, Simone Kats, Jeffrey Justin Estella, Ivan De Dios, Wanlong Ma, Andrew L. Pecora, Andre H. Goy, Jamie Koprivnikar, James K. McCloskey, Maher Albitar
Publikováno v:
Frontiers in oncology. 12
IntroductionCytogenetic analysis is important for stratifying patients with various neoplasms. We explored the use of targeted next generation sequencing (NGS) in detecting chromosomal structural abnormalities or copy number variations (CNVs) in pati
Autor:
Eric V Schultz, John Hervey, Stanley E. Waintraub, Phillip M Francis, Lisa M. Latts, Cody Landstrom, Nicholas Jungbluth, Deena Graham, Ching-Kun Wang, Andrew L. Pecora, Stuart L. Goldberg, Jane L. Snowdon, Andrew D. Norden, Donna M. McNamara
Publikováno v:
Cancer Medicine, Vol 8, Iss 15, Pp 6578-6584 (2019)
Cancer Medicine
Cancer Medicine
Introduction Cognitive computing point‐of‐care decision support tools which ingest patient attributes from electronic health records and display treatment options based on expert training and medical literature, supplemented by real world evidenc
Autor:
Maher Albitar, Hong Zhang, Ahmad Charifa, Andrew Ip, Ivan De Dios, Wanlong Ma, James McCloskey, Michele Donato, David Samuel DiCapua Siegel, Stanley E. Waintraub, Martin Gutierrez, Andrew L Pecora, Andre Goy
Publikováno v:
Journal of Clinical Oncology. 40:3047-3047
3047 Background: Expressed RNA can capture mutations, changes in expression levels due to methylation, and provide information on cell of origin, growth, and proliferation status. We developed an approach to isolate fragmented RNA from peripheral blo
Autor:
Maher Albitar, Hong Zhang, Ahmad Charifa, Andrew Ip, Ivan De Dios, Wanlong Ma, James K. McCloskey, Michele Donato, David Samuel DiCapua Siegel, Stanley E. Waintraub, Martin Gutierrez, Andrew L Pecora, Andre Goy
Publikováno v:
Journal of Clinical Oncology. 40:3048-3048
3048 Background: Expressed RNA can capture mutations, gene fusions, and biomarker profiles. In principle, each abnormal cell has one copy of mutated gene, but numerous copies of mutated RNA. Cell-free RNA (cfRNA) is not used due to the assumption tha
Autor:
Hong Zhang, Maher Albitar, Muhammad Asif Qureshi, Mohsin Wahid, Ahmad Charifa, Aamir Ehsan, Andrew Ip, Ivan De Dios, Wanlong Ma, James McCloskey, Michele Donato, David Samuel DiCapua Siegel, Martin Gutierrez, Andrew L Pecora, Andre Goy
Publikováno v:
Journal of Clinical Oncology. 40:3018-3018
3018 Background: Diagnosis and classification of tumors is becoming increasingly dependent on biological and molecular biomarkers. RNA expression profiling using next generation sequencing (NGS) provides information on various biological and molecula
Autor:
Daniela Annenelie Bota, Behnam Badie, Amy B. Heimberger, Nazanin Majd, Mark S. Awadalla, John Colerangle, Shawn He, Sharmila Koppisetti, William van der Touw, Robert Hariri, Andrew L Pecora
Publikováno v:
Journal of Clinical Oncology. 40:TPS2080-TPS2080
TPS2080 Background: CYNK-001 is a CD56+CD3- enriched, off-the-shelf, allogeneic natural killer (NK) cell product expanded from placental CD34 cells. CYNK-001 exhibits in vitro cytotoxicity against patient-derived GBM cell lines and secretes cytolytic
Autor:
Victoria DeVincenzo, Joshua Richter, Brooke Grunman, David S. Siegel, Noa Biran, Andrew L. Pecora, Kathryn Tanenbaum, Larysa Sanchez, Ching-Kun Wang, David H. Vesole, Stuart L. Goldberg
Publikováno v:
Clinical lymphoma, myelomaleukemia. 21(3)
Background Advances in the management of multiple myeloma (MM) have extended survival and reduced painful skeletal-related events. As MM is evolving toward a chronic disease, we sought to determine the prevalence of self-reported symptom burden and p
Autor:
Juan C. Paramo, Sajeve S. Thomas, William Schmidt, Pallavi Kumar, Eddy C. Hsueh, Deepti Behl, Vinay Kumar Gupta, Prejesh Philips, Edward C. McCarron, Arvinda Padmanabhan, Adam C. Berger, Daniel Milton, Tawnya L. Bowles, Robert Weber, Jeffrey B Travers, Brendan D. Curti, Suthee Rapisuwon, Robert H.I. Andtbacka, Peter D. Beitsch, Mohammed M. Milhem, Edward A. Levine, John R. Hyngstrom, Suprith Badarinath, Anna Bar, John Keech, Marcus O. Butler, Omid Hamid, Brian R. Gastman, Andrew L. Pecora, Craig L. Slingluff, Takami Sato, J. Thaddeus Beck, Sekwon Jang, Catalin Mihalcioiu, John A. Glaspy, Karl D. Lewis, Shernan G. Holtan, Joël Claveau, Montaser Shaheen, Leonel Hernandez-Aya, Jose Lutzky, Brent A. Blumenstein, Joanna J Peterkin, Svetomir N. Markovic, Sujith Kalmadi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundMost patients with advanced melanomas relapse after checkpoint blockade therapy. Thus, immunotherapies are needed that can be applied safely early, in the adjuvant setting. Seviprotimut-L is a vaccine containing human melanoma antigens, plu
Autor:
Martin Gutierrez, Andrew L. Pecora, Ruth Pe Benito, Edward J. Licitra, Sukhi Kaur, Eric V Schultz, Richard B. Lanman, Stuart L. Goldberg, Stanley M. Skrzypczak, Kelly Choi, Tommy Wu, Harry D. Harper, Srikesh Arunajadai
Publikováno v:
Clinical Lung Cancer. 18:651-659
National guidelines have advocated broad molecular profiling as a part of the standard diagnostic evaluation for advanced non-small cell lung cancer (NSCLC), with the goal of identifying driver mutations for which effective therapies or clinical tria